Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06003881
Status:
AVAILABLE
Last Update Posted:
2023-08-22
First Post:
2023-08-14
Brief Title:
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Study Overview
Official Title:
An Open-Label Expanded Access Program of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy CHAPLE Disease
Status:
AVAILABLE
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHAPLE Disease
Brief Summary:
The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy PLE CD55-deficient PLECHAPLE disease is a rare inherited disease of the immune system This can be a life-threatening condition that is usually found when patients are children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None